placeSouth Africa
Contact us
Minimally Invasive Therapies / Clinical Solutions / Critical Congenital Heart Defects / CCHD Newborns

YOU ARE ENTERING HCP CONTENT ONLY

Please note you are entering now content intended only for Healthcare Professionals.

Are you a HCP?

Critical Congenital Heart Defects (CCHD) and Pulse Oximetry Screening

Approximately 1 in 500 babies is born with a critical congenital heart defect (CCHD). These babies are at a significant risk if this condition goes undiagnosed.1 As it can cause serious, life-threatening symptoms, early detection and intervention is essential.

In 2017, the European Pulse Oximetry Screening Workgroup published a consensus in which they state that adopting POS at a national level across Europe will help improve management of these life threatening conditions.2

Screening should be performed with pulse oximeters that are motion tolerant, report functional oxygen saturation, have been validated in low perfusion conditions, have been cleared by the FDA for use in newborns and have accuracy of +/- 2 digits.3

Motion Tolerant. Clinician Tested.

Our Nellcor™ pulse oximetry portfolio facilitates quick, noninvasive screenings for CCHD. The products are U.S. Food and Drug Administration (FDA)-510(k) cleared for use on neonates, have been labeled as a tool to aid in CCHD screenings, and are motion tolerant, so you can confidently rely on them for accurate CCHD screenings.

Additionally, since 1993, Nellcor™ pulse oxumetry technology has been utililsed on more than 33,000 newborns spanning five separates clinical studies evaulating the use of pulse oximetry for critical congenital heart disease screening.

UNSURPASSED ACCURACY. DEPENDABLE PERFORMANCE.

Nellcor™ pulse oximetry technology specifies highly accurate readings in neonates, largely because it relies on cardiac-based signals to generate readings closely tied to the patient’s physiology. The result is consistent performance during a number of challenging conditions, including patient motion, noise, and low perfusion, all of which can impede the assessment of oxygenation.

Using Nellcor™ pulse oximetry has been shown to be a simple and economical tool to aid healthcare providers in CCHD screening.

RECOMMENDED PRODUCT

Nellcor™ Pulse Oximetry for continuous SpO2, pulse rate and respiration rate monitoring

Proven Technology, State-of-the-Art Design

  • 1. Scott D. Grosse, PhD1; Tiffany Riehle-Colarusso, MD1; Marcus Gaffney, MPH1; Craig A. Mason, PhD2; Stuart K. Shapira, MD, PhD1; Marci K. Sontag, PhD3; Kim Van Naarden Braun, PhD1,4; John Iskander, MD5. CDC Grand Rounds: Newborn Screening for Hearing Loss and Critical Congenital Heart Disease. 2017;66(33);888–890. Available at
  • 2. Paolo Manzoni, Gerard R Martin, Manuel Sanchez Luna, Julije Mestrovic, Umberto Simeoni, Luc Zimmermann, and others. Pulse oximetry screening for critical congenital heart defects: A European consensus statement. The Lancet Child & Adolescent Health, 2017;1(2), p8–90.
  • 3. Kemper AR, Mahle WT, Martin GR et al. Strategies for implementing screening for critical congenital heart disease. Pediatrics. 2011;128(5):e1259-1267
CORPORATE RESOURCES
Minimally Invasive Therapies
Medtronic Africa

Waterfall Distribution Campus

Corner K101 & Bridal Veil Road

Waterfall, Midrand, Gauteng

1685

South Africa

©2025 Medtronic